Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

  • STATUS
    Recruiting
  • End date
    Sep 26, 2022
  • participants needed
    84
  • sponsor
    Novartis Pharmaceuticals
Updated on 16 May 2021
lung transplant
idiopathic pulmonary fibrosis
diffusion capacity of the lung for carbon monoxide

Summary

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Details
Condition Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, usual interstitial pneumonia
Treatment Placebo, VAY736
Clinical Study IdentifierNCT03287414
SponsorNovartis Pharmaceuticals
Last Modified on16 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note